otud5a Antibody

What is OTUD5 and why is it important in research?

OTUD5 is a deubiquitinase belonging to the OTU (Ovarian Tumor) superfamily that selectively removes ubiquitin chains from target proteins. Its significance lies in its diverse biological functions, including regulation of innate immunity, embryonic development, and viral replication. OTUD5 has been identified as essential for embryonic development through genomic constraint analysis, with knockout studies in mice demonstrating embryonic lethality . In HBV research, OTUD5 has been found to promote viral replication by stabilizing viral core proteins through deubiquitination . The critical nature of OTUD5 in multiple cellular processes makes it an important target for researchers studying ubiquitin-mediated regulation of cell signaling and development.

What are the validated applications for OTUD5 antibodies in research?

OTUD5 antibodies have been successfully applied in several research techniques:

• Western blotting - For detection of OTUD5 protein expression levels in cell lysates (e.g., comparing HepG2.2.15 and HepG2 cell lines)

• Immunohistochemistry (IHC) - For visualization of OTUD5 expression in liver tissues from HBV-infected versus non-infected samples

• Immunoprecipitation - For studying protein-protein interactions of OTUD5 with potential binding partners

• Immunofluorescence - For examining subcellular localization (particularly nuclear versus cytoplasmic distribution)

• ELISA - For quantification of OTUD5 in serum samples from patients

These applications have been validated in peer-reviewed studies examining OTUD5's role in disease contexts, particularly HBV infection and developmental disorders.

What are the known isoforms of OTUD5 and how do antibodies detect them?

OTUD5 exists in multiple isoforms due to alternative splicing. The primary research-validated antibodies target:

When selecting antibodies, researchers should consider which isoform is relevant to their study. Some antibodies may detect all isoforms while others are specific to particular variants or post-translational modifications. Western blot validation is recommended to confirm detection of the correct isoform in your experimental system .

How can OTUD5 antibodies be used to investigate deubiquitinase activity and substrate specificity?

Investigating OTUD5's deubiquitinase activity requires sophisticated experimental approaches:

• In vitro deubiquitination assays: Combine immunoprecipitated OTUD5 (using anti-OTUD5 antibodies) with synthesized ubiquitin chains (K48 or K63-linked) and monitor cleavage activity using Western blot with anti-ubiquitin antibodies. Studies have demonstrated that wild-type OTUD5 efficiently cleaves K48-linked ubiquitin chains, while disease-associated variants (e.g., p.Leu352Pro) show reduced activity .

• Substrate identification: Use OTUD5 antibodies for co-immunoprecipitation followed by mass spectrometry to identify interaction partners. Research has identified HBV core/precore proteins as substrates, showing that OTUD5 removes their K48-linked ubiquitination chains .

• Activity-based profiling: Combine activity-based probes for DUBs with OTUD5 antibodies to assess the catalytic activity of OTUD5 in different cellular contexts.

• Phosphorylation-dependent activity: Investigate how phosphorylation affects OTUD5 activity using phospho-specific antibodies alongside standard OTUD5 antibodies.

This multi-faceted approach can reveal the complex regulatory mechanisms controlling OTUD5's substrate specificity and activity under different cellular conditions.

What experimental approaches can distinguish between OTUD5's role in different signaling pathways?

OTUD5 operates at the intersection of multiple signaling pathways. To dissect its pathway-specific functions:

• Pathway inhibitor studies: Combine OTUD5 immunodetection with ERK1/2 pathway inhibitors. Research has shown that OTUD5 inhibits the ERK1/2 MAPK signaling pathway to accumulate HNF4α expression, benefiting HBV replication .

• Phosphoprotein profiling: Use antibody panels targeting OTUD5 alongside phosphorylated forms of p38, ERK1/2, and JNK to track MAPK pathway modulation by OTUD5.

• Chromatin immunoprecipitation (ChIP): Apply OTUD5 antibodies for ChIP followed by sequencing to identify genomic regions where OTUD5 may influence transcription factor binding, particularly for factors like HNF4α.

• Proximity labeling: Combine OTUD5 antibodies with BioID or APEX2 proximity labeling to identify pathway-specific interactors in different cellular compartments.

This comprehensive approach allows for precise characterization of OTUD5's distinct roles in different cellular contexts.

How can OTUD5 antibodies be used to investigate its role in HBV replication and potential therapeutic targeting?

OTUD5 antibodies enable several experimental strategies to explore its role in HBV infection:

• Viral protein stabilization assays: Use anti-OTUD5 and anti-HBV core antibodies to analyze how OTUD5 manipulates HBV protein stability. Research has shown that OTUD5 removes K48-linked ubiquitin chains from HBV core/precore proteins, protecting them from proteasomal degradation .

• OTUD5 inhibition studies: Monitor HBsAg, HBeAg, and HBV-DNA levels following OTUD5 knockdown or inhibition. Studies demonstrate that OTUD5 knockdown significantly downregulates HBV replication and transcription .

• Clinical correlation analysis: Use quantitative ELISA with OTUD5 antibodies to measure serum OTUD5 levels in HBV patients. Research has shown that OTUD5 concentration can predict HBeAg seroconversion, with a cutoff value of 2.34 ng/mL identified as predictive in ROC curve analysis .

• Therapeutic target validation: Employ OTUD5 antibodies to assess the impact of potential DUB inhibitors on OTUD5-HBV interactions and subsequent viral replication.

These approaches can help identify whether OTUD5 inhibition represents a viable therapeutic strategy against HBV infection, as suggested by recent research .

What are the optimal fixation and sample preparation protocols for OTUD5 immunodetection in different tissues?

Optimal detection of OTUD5 requires specific sample preparation protocols based on the application:

• Immunohistochemistry (IHC):

  • Fixation: 10% neutral buffered formalin for 24-48 hours

  • Antigen retrieval: Citrate buffer (pH 6.0) heat-induced epitope retrieval

  • Blocking: 5% normal goat serum in PBS with 0.1% Triton X-100

  • Primary antibody dilution: 1:100-1:200 (validated for liver tissue sections)

  • Detection system: HRP-conjugated secondary antibody with DAB substrate

• Immunofluorescence (IF):

  • Fixation: 4% paraformaldehyde for 15 minutes

  • Permeabilization: 0.2% Triton X-100 for 10 minutes

  • Blocking: 3% BSA in PBS

  • Primary antibody dilution: 1:200-1:500

  • Counterstaining: DAPI for nuclear visualization

• Western blotting:

  • Lysate preparation: RIPA buffer with protease inhibitors

  • Protein loading: 20-40 μg per lane

  • Transfer: Wet transfer recommended for optimal results

  • Blocking: 5% non-fat dry milk in TBST

  • Primary antibody dilution: 1:1000-1:2000

  • Recommended controls: HepG2.2.15 cells as positive control

These optimized protocols help ensure specific detection while minimizing background and false positives across different experimental systems.

How should researchers validate OTUD5 antibody specificity for their experimental system?

Comprehensive validation of OTUD5 antibodies should include:

• Knockout/knockdown controls:

  • Use CRISPR-Cas9 knockout or siRNA knockdown cells alongside wild-type cells

  • Verify complete loss or reduction of signal in Western blot and immunostaining

  • Studies have used OTUD5 knockdown plasmids with GFP tags or CRISPR-Cas9 knockout plasmids to confirm antibody specificity

• Overexpression controls:

  • Overexpress tagged OTUD5 and confirm increased signal intensity

  • Test for co-localization between antibody signal and tag-specific antibodies

  • OTUD5 lentivirus expression plasmids with RFP tags have been used for this purpose

• Cross-reactivity assessment:

  • Test antibody against related OTU family deubiquitinases (OTUD1-4, OTUD6A/B)

  • Examine tissues with known differential expression of OTUD5

• Epitope blocking:

  • Pre-incubate antibody with immunizing peptide before application

  • Verify signal elimination when the epitope is blocked

• Multiple antibody concordance:

  • Compare results using antibodies targeting different epitopes of OTUD5

  • Consistent results across antibodies increase confidence in specificity

Proper validation ensures reliable experimental outcomes and prevents misinterpretation of data due to non-specific binding.

What are the best practices for using OTUD5 antibodies in co-immunoprecipitation studies investigating protein-protein interactions?

Successful co-immunoprecipitation (co-IP) with OTUD5 antibodies requires:

• Lysis buffer optimization:

  • Use gentle lysis buffers (e.g., 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA)

  • Include protease inhibitors, phosphatase inhibitors, and DUB inhibitors (N-ethylmaleimide)

  • For ubiquitinated substrates, add 2-10 mM N-ethylmaleimide to prevent deubiquitination during lysis

• Antibody selection and controls:

  • Choose antibodies validated for IP applications

  • Include isotype control antibodies as negative controls

  • Perform reverse IP when possible (IP with antibody against suspected interactor)

• Optimized protocol for OTUD5-substrate interactions:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Use 1-5 μg antibody per 500 μg protein lysate

  • Incubate with antibody overnight at 4°C with gentle rotation

  • Wash extensively (at least 4-5 times) with cold lysis buffer

• Detection of ubiquitinated species:

  • Use K48-linkage specific antibodies to detect ubiquitinated substrates

  • Include proteasome inhibitors in cell culture prior to lysis

  • Research has shown that OTUD5 removes K48-linked ubiquitin chains from HBV core/precore proteins, which can be detected using linkage-specific antibodies

• Data analysis considerations:

  • Quantify band intensities relative to input

  • Present data as enrichment over isotype control

  • Validate key interactions with alternative methods (proximity ligation assay, FRET)

Following these guidelines will maximize the chances of detecting genuine OTUD5 protein interactions while minimizing artifacts.

How can OTUD5 antibodies be applied in clinical research for HBV infection and therapy monitoring?

OTUD5 antibodies have emerging applications in clinical HBV research:

• Serum biomarker development:

  • ELISA-based quantification of OTUD5 in patient serum samples

  • Research has shown OTUD5 levels are significantly higher in HBV carriers compared to healthy individuals, and even higher in chronic hepatitis B (CHB) patients

  • Established cutoff value of 2.34 ng/mL for predicting HBeAg seroconversion in CHB patients receiving antiviral therapy

• Therapy monitoring:

  • Track OTUD5 levels during antiviral treatment

  • Lower OTUD5 levels correlate with higher probability of HBeAg seroconversion

  • ROC curve analysis demonstrated OTUD5 as a predictive biomarker for treatment response

• Liver tissue analysis:

  • IHC staining of liver biopsies shows increased cytoplasmic OTUD5 expression in chronic hepatitis B tissues compared to HBV-negative liver tissues

  • Can be used to assess intrahepatic OTUD5 distribution and correlation with disease progression

• Sample collection and processing standardization:

  • Blood collection: Standard serum separator tubes

  • Processing time: Within 2 hours of collection

  • Storage: -80°C for long-term storage

  • Avoid repeated freeze-thaw cycles

This emerging biomarker application represents a potential clinical translation of fundamental OTUD5 research, providing predictive information about treatment outcomes in chronic HBV infection .

What techniques can be used to investigate OTUD5's role in embryonic development and developmental disorders?

OTUD5 antibodies enable several experimental approaches to study developmental roles:

• Stem cell differentiation models:

  • Track OTUD5 expression during differentiation of pluripotent stem cells

  • Research shows significant upregulation of OTUD5 during neural conversion of iPSCs

  • Use dual-SMAD inhibition protocols to direct differentiation toward CNS precursor and neural crest cells

• Patient-derived cellular models:

  • Generate iPSCs from patients with OTUD5 mutations

  • Perform teratoma formation assays and neural conversion

  • Research has identified defects in neuroectoderm differentiation in patient cells expressing the p.Gly494Ser allele

• Developmental timing analysis:

  • Track OTUD5 expression across embryonic developmental stages

  • Compare wild-type versus mutant OTUD5 effects on differentiation markers

• Subcellular localization studies:

  • Assess OTUD5 nuclear versus cytoplasmic distribution during development

  • Research has shown that p.Arg274Trp mutation affects nuclear localization of OTUD5

These approaches can elucidate OTUD5's critical role in embryonic development and the pathogenesis of LINKED syndrome.

What are common issues with OTUD5 antibodies and how can they be resolved?

Researchers frequently encounter these challenges when working with OTUD5 antibodies:

• Low signal intensity in Western blots:

  • Problem: Weak bands despite adequate protein loading

  • Solutions:

    • Increase antibody concentration (1:500 instead of 1:1000)

    • Extend primary antibody incubation to overnight at 4°C

    • Use enhanced sensitivity detection systems (ECL Plus)

    • Optimize antigen retrieval for fixed samples

• High background in immunostaining:

  • Problem: Non-specific staining obscuring specific signal

  • Solutions:

    • Increase blocking time and concentration (5% BSA for 2 hours)

    • Include 0.1% Tween-20 in antibody diluent

    • Perform additional washing steps (6 x 5 minutes)

    • Use directly conjugated primary antibodies to eliminate secondary antibody background

• Inconsistent immunoprecipitation results:

  • Problem: Variable pull-down efficiency across experiments

  • Solutions:

    • Use magnetic beads instead of agarose for more consistent recovery

    • Pre-clear lysates thoroughly before adding antibody

    • Standardize lysate concentration precisely before IP

    • Consider crosslinking antibody to beads to prevent heavy chain interference

• Discrepancies between different OTUD5 antibodies:

  • Problem: Different antibodies yield inconsistent results

  • Solutions:

    • Confirm epitope locations of different antibodies

    • Test for isoform specificity with recombinant protein controls

    • Validate antibodies with OTUD5 knockout/knockdown samples

    • Consider post-translational modifications that might affect epitope recognition

Implementing these solutions can significantly improve experimental consistency and reliability when working with OTUD5 antibodies.